A phase 2/3, randomized, open-label, multicenter study to evaluate the safety and efficacy of FPI-2265 (225Ac-PSMA-I&T) in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), previously treated with 177Lu-PSMA radioligand therapy (RLT)

Description

This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I\&T). Patient population is adult participants with PSMA positive mCRPC who have had previous treatment with with 177Lu-PSMA-617 or another 177Lu-PSMA radioconjugate (RC). The purpose of the study is to determine the safety and tolerability, and recommended dose and regiment of FPI-2265.

Resources and Links

Phone Number: 1-877-MDA-6789

clinicaltrials.gov NCT No: NCT06402331 Opens a new window